Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK’s Prices Breo On Par With Advair For COPD

This article was originally published in The Pink Sheet Daily

Executive Summary

The wholesale acquisition cost of GlaxoSmithKline’s once-daily COPD medication Breo is the same as Advair, reflecting the high reimbursement hurdle for new respiratory medicines.


Related Content

Breo Launch Timing Slips But No “Drama,” GSK’s Witty Says
Breo Inverts Traditional Path To COPD Indication For LABA Combinations
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
COPD Market Snapshot: New Products, Limited Differentiation
Teva Has Grand Ambitions In Respiratory Disease, With An Eye On Advair


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts